Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by its aggressive behavior and high tumor heterogeneity. This type of cancer represents approximately 15% of all breast cancer cases and is known for a high rate of early metastasis and recurrence, leading to a challenging prognosis. The mortality rate for TNBC can be severe, with many patients facing a 40% chance of death within the first five years after diagnosis. This underscores the need for effective diagnostics and treatments to improve outcomes for these patients.
Genetic diagnosis plays a crucial role in establishing personalized treatment options for TNBC. Identifying genetic variants associated with hereditary cancer (HC) is essential in understanding the predisposition to this aggressive cancer type. Existing studies suggest that hereditary factors account for 5% to 10% of cancers, though this may be underrepresented in certain populations. In particular, identifying mutations in known cancer susceptibility genes significantly contributes to refining targeted therapies and enhancing early detection strategies for patients and their families.
In this study, researchers embarked on validating the use of whole-exome sequencing (WES) to provide a genetic diagnosis for patients diagnosed with TNBC. A total of 24 patients participated in the TNBC discovery cohort, while a second cohort of 25 individuals with previously identified hereditary cancer syndromes served as a validation group. The study complied with ethical guidelines, and all participants provided informed consent prior to genetic testing.
The methodology involved extracting genomic DNA from the participants’ blood samples, followed by WES library preparation using standard protocols. Sequencing was conducted on platforms designed for high-throughput analyses, ensuring broad coverage of relevant coding regions.
Additionally, a comprehensive bioinformatics pipeline was developed for variant detection. This pipeline incorporated the best practices for genomic data analysis, offering a reproducible approach to sequencing data evaluation and variant annotation.
The research confirmed the feasibility of using the developed bioinformatics pipeline to identify alterations in cancer susceptibility genes. Among the 24 TNBC patients, three pathogenic germline variants were identified in the following genes: ATM, RAD51D, and BRCA1. These genes are integral components of the DNA repair pathway, and their mutations can significantly affect cancer susceptibility. The findings from the TNBC discovery cohort demonstrate the potential of WES in revealing significant hereditary factors associated with disease predisposition.
The results suggest that the developed pipeline not only shows promise in identifying variants in a cohort known for underrepresentation in genetic studies, but it also provides a robust framework applicable beyond TNBC to various cancers with suspected hereditary links.
The identification of germline variants in genes relevant to hereditary cancer syndromes enhances the opportunity for personalized risk assessment and therapeutic strategies for individuals with TNBC. This study emphasizes the importance of utilizing comprehensive genetic testing, such as WES, compared to traditional smaller panels which may overlook critical variants due to their limited scope.
The ability to detect multiple variants across a wide panel of genes facilitates earlier diagnosis and tailored treatment plans, promoting improved patient outcomes and potentially reducing recurrence rates. Enhancing genetic literacy in clinical practice regarding hereditary risks is vital for implementing effective management plans for at-risk patients and their families.
The implementation of a bioinformatics pipeline for exome-based genetic analysis in TNBC shows significant promise for enhancing genetic diagnosis capabilities. This approach has the potential to advance our understanding of hereditary components underlying TNBC and aims to enrich clinical strategies that can lead to better patient management, early cancer detection, and personalized therapies. This study highlights the imperative need for further research into genetic testing as a cornerstone of oncology, aligning treatment modalities with the genetic profiles of patients to foster more targeted and efficacious interventions.